drugset / Trial / NCT04922047
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
Phase 1/2
Unknown
6 enrolled
RenJi Hospital
BeiGene · collabHuidu Shanghai Medical Sciences Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, single-center study to assess the safety of tislelizumab with BCG, and to obtain the preliminary efficacy results in subjects who have been diagnosed with high-risk NMIBC without prior BCG treatment.
Timeline
- Start
- 2021-06
- Primary completion
- 2021-12
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Bacille Calmette-Guérin | Unknown | 120 mg | Other |